Probiodrug AG Presents Development Overview Of PQ912, Probiodrug’s QC-Inhibitor For Alzheimer’s Disease
7/10/2014 6:20:59 AM
HALLE/SAALE, Germany--(BUSINESS WIRE)--Probiodrug AG (Probiodrug) announced that Prof. Hans-Ulrich Demuth, co-founder and consultant to the company, will give a talk detailing clinical development of PQ912 at the upcoming Alzheimer’s Association International Conference in Copenhagen, Denmark. The presentation, titled: “Toxic pGlu-Abeta is enhanced and Glutaminyl Cyclase (QC) up-regulated early in Alzheimer's Disease (AD) - Inhibitors of QC Blocking pGlu-Abeta Formation are in Clinical Development,” summarizes target validation and pharmacological studies supporting the treatment of Alzheimer’s disease (AD) by lowering modified and toxic pyroglutamated (pGlu) Abeta through the inhibition of glutaminyl cyclase (QC). The presentation provides Phase 1 clinical results and development status of PQ912, the company’s lead QC-inhibitor. Dr. Demuth’s presentation takes place Sunday, July 13 from 16:00 to 17:30 in the “Therapeutics: Clinical” session.
Help employers find you! Check out all the jobs and post your resume.
comments powered by